{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:22:57Z","timestamp":1772799777071,"version":"3.50.1"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,8,30]]},"DOI":"10.18632\/oncotarget.2244","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:38:51Z","timestamp":1442360331000},"page":"6734-6745","source":"Crossref","is-referenced-by-count":38,"title":["RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis"],"prefix":"10.18632","volume":"5","author":[{"given":"Yuting","family":"Huang","sequence":"first","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, P.R. China"},{"name":"Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"issue":"1","key":"1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Jemal","year":"2014","journal-title":"CA: a cancer journal for clinicians"},{"issue":"5","key":"2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1101\/gad.1399806","article-title":"Control of translation and mRNA degradation by miRNAs and siRNAs","volume":"20","author":"Parker","year":"2006","journal-title":"Genes & development"},{"issue":"1","key":"3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-13-2063","article-title":"Discrete Molecular Classes of Ovarian Cancer Suggestive of Unique Mechanisms of Transformation and Metastases","volume":"20","author":"Bapat","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"4","article-title":"Epithelial-mesenchymal transition (EMT) gene variants influence epithelial ovarian cancer risk in women of European, African and Asian ancestry","volume":"73","author":"Narod","year":"2013","journal-title":"Cancer research"},{"issue":"11","key":"5","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.humpath.2013.05.001","article-title":"Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma","volume":"44","author":"Liu","year":"2013","journal-title":"Human pathology"},{"issue":"22","key":"6","doi-asserted-by":"crossref","first-page":"E1974","DOI":"10.1073\/pnas.1216989110","article-title":"Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules","volume":"110","author":"Hasan","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrm1835","article-title":"Complex networks orchestrate epithelial-mesenchymal transitions","volume":"7","author":"Sleeman","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Weinberg","year":"2009","journal-title":"J Clin Invest"},{"issue":"5","key":"9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-Mesenchymal Transitions in Development and Disease","volume":"139","author":"Nieto","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc3447","article-title":"Regulatory networks defining EMT during cancer initiation and progression","volume":"13","author":"Berx","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/ncb2976","article-title":"Oncogenic roles of EMT-inducing transcription factors","volume":"16","author":"Caramel","year":"2014","journal-title":"Nature cell biology"},{"issue":"8","key":"12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.18632\/oncotarget.1136","article-title":"HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness","volume":"4","author":"Manfioletti","year":"2013","journal-title":"Oncotarget"},{"issue":"11","key":"13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Bar-Sagi","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Wittinghofer","year":"2007","journal-title":"Cell"},{"issue":"12","key":"15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc2960","article-title":"Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?","volume":"10","author":"Der","year":"2010","journal-title":"Nature reviews Cancer"},{"issue":"2","key":"16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ajpath.2012.04.011","article-title":"ECT2 and RASAL2 mediate mesenchymal-amoeboid transition in human astrocytoma cells","volume":"181","author":"Rutka","year":"2012","journal-title":"The American journal of pathology"},{"issue":"3","key":"17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccr.2013.08.004","article-title":"The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor","volume":"24","author":"Cichowski","year":"2013","journal-title":"Cancer cell"},{"issue":"4","key":"18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ccr.2013.09.007","article-title":"Origins of Metastatic Traits","volume":"24","author":"Massagu\u00e9","year":"2013","journal-title":"Cancer cell"},{"issue":"11","key":"19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer","volume":"7","author":"Kaye","year":"2006","journal-title":"Lancet Oncology"},{"key":"20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.cellbio.22.010305.104219","article-title":"Tight junctions and cell polarity","volume":"22","author":"Margolis","year":"2006","journal-title":"Annual review of cell and developmental biology"},{"key":"21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.cellbio.19.011102.111135","article-title":"Cadherins as modulators of cellular phenotype","volume":"19","author":"Johnson","year":"2003","journal-title":"Annual review of cell and developmental biology"},{"issue":"3","key":"22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Derynck","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kaye","year":"2013","journal-title":"Nature reviews Cancer"},{"issue":"5","key":"24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrc1611","article-title":"Ovarian cancer metastasis: Integrating insights from disparate model organisms","volume":"5","author":"Montell","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.18632\/oncoscience.31","article-title":"Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells","volume":"1","author":"Petignat","year":"2014","journal-title":"Oncoscience"},{"issue":"24","key":"26","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1158\/0008-5472.CAN-09-1257","article-title":"Epithelial-to-Mesenchymal Transition and Ovarian Tumor Progression Induced by Tissue Transglutaminase","volume":"69","author":"Matei","year":"2009","journal-title":"Cancer research"},{"issue":"12","key":"27","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-12-3832","article-title":"Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis","volume":"73","author":"Kipps","year":"2013","journal-title":"Cancer research"},{"issue":"5","key":"28","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1158\/0008-5472.CAN-12-2377","article-title":"ALX1 Induces Snail Expression to Promote Epithelial-to-Mesenchymal Transition and Invasion of Ovarian Cancer Cells","volume":"73","author":"Senga","year":"2013","journal-title":"Cancer research"},{"issue":"16","key":"29","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-07-6302","article-title":"p70 S6 kinase promotes epithelial to mesenchymal transition through Snail induction in ovarian cancer cells","volume":"68","author":"Wong","year":"2008","journal-title":"Cancer research"},{"issue":"6","key":"30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Mills","year":"2009","journal-title":"Nature reviews Cancer"},{"issue":"1","key":"31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4293","article-title":"Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants","volume":"232","author":"Shih","year":"2014","journal-title":"Journal of Pathology"},{"issue":"19","key":"32","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-12-1103","article-title":"Pre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A and RAS Pathway Aberrations","volume":"18","author":"Australian Ovarian Canc Study","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/path.4252","article-title":"KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma","volume":"231","author":"Wong","year":"2013","journal-title":"Journal of Pathology"},{"issue":"3","key":"34","first-page":"272","article-title":"Dragging Ras Back in the Ring","volume":"25","author":"McCormick","journal-title":"Cancer cell"},{"issue":"3","key":"35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health","volume":"2","author":"Mijatovic","year":"2011","journal-title":"Oncotarget"},{"key":"36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.18632\/oncoscience.26","article-title":"Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor","volume":"1","author":"Selvendiran","year":"2014","journal-title":"Oncoscience"},{"key":"37","first-page":"21","article-title":"Disulfiram\/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition","volume":"1","author":"Bruning","year":"2014","journal-title":"Oncoscience"},{"key":"38","first-page":"5","article-title":"MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors","volume":"11","author":"Hong","year":"2014","journal-title":"Oncoscience"},{"issue":"12","key":"39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.4161\/cbt.27350","article-title":"Selective anti-cancer agents as anti-aging drugs","volume":"14","author":"Blagosklonny","year":"2013","journal-title":"Cancer biology & therapy"},{"issue":"10","key":"40","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance","volume":"3","author":"Maksimovic-Ivanic","year":"2012","journal-title":"Oncotarget"},{"issue":"9","key":"41","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/cdd.2013.86","article-title":"MEK drives cyclin D1 hyperelevation during geroconversion","volume":"20","author":"Blagosklonny","year":"2013","journal-title":"Cell death and differentiation"},{"issue":"12","key":"42","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1541-7786.MCR-13-0332-T","article-title":"Activation of the Wnt pathway through AR79, a GSK3beta inhibitor, promotes prostate cancer growth in soft tissue and bone","volume":"11","author":"Keller","year":"2013","journal-title":"Molecular cancer research : MCR"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T10:32:08Z","timestamp":1599561128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":42,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2014,8,30]]}},"alternative-id":["2244","25216515"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2244","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,23]]}}}